explore -WSS

explore

author：comprehensive 2025-10-02 22:26:52 - browse：299

AstraZeneca said Friday it will buy up a group of early-stage gene therapies from Pfizer, bucking a trend of drugmakers axing programs and exiting a field that had once captured the imagination — and checkbooks — of many pharmaceutical executives.

AstraZeneca will pay Pfizer up to $1 billion plus royalties for the portfolio of treatments, none of which has entered clinical trials yet. The companies did not say how much it is paying upfront.

The moves come six months after Pfizer said it would stop much of its work on early-stage gene therapy programs, in which researchers try to deliver replacement genes encased in small, non-pathogenic bugs called adeno-associated viruses, or AAVs. Instead, it would focus on newer technologies, such as gene editing.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Continuity nursing helped my family in our darkest PICU moments
Next article： FDA has safety concerns on CRISPR

WSS

Biden report: The neurospychology of memory and aging

Gilead might be held responsible for not developing a drug

The pink breast cancer awareness ribbon needs a redesign

Readout LOUD podcast: How biotech is using artificial intelligence

PhRMA lawsuit over Medicare drug price negotiation tossed

PhRMA lawsuit over Medicare drug price negotiation tossed

hotspot

explore

entertainment

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Gilead might be held responsible for not developing a drug

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Gilead acquiring CymaBay and its liver disease drug for $4.3 billion

Moonlake's readout produced a cash windfall. Risks remain

KalVista pill reduced swelling 'attacks' caused by genetic disease

New air purifier tech could be key to improving indoor air quality

Emergency medicine has repudiated 'excited delirium.' Now what?

Bright Health sells Medicare Advantage business to Molina

For Medicare Advantage, Democrats want stronger protections around AI

focus

The pink breast cancer awareness ribbon needs a redesign

A ‘polypill’ could sharply reduce cardiovascular disease in the U.S.

Physician subsidies by hospitals soar in wake of No Surprises Act

Readout Newsletter: What happened with Sarepta's Duchenne data

Medicare Advantage proposed rates disappoint insurers

For Medicare Advantage, Democrats want stronger protections around AI

hotspot

explore

hotspot

focus